£111.00
Additional information
| Active substance | Tesofensine |
|---|---|
| Water Retention | No significant water retention reported |
| Hepatotoxicity | No significant hepatotoxic effects known |
| Lab Test | Plasma levels can be monitored through blood tests |
| Also known as | NS2330 |
| Blood pressure | Can cause increases in blood pressure |
| Trade name | Not commercially available under a specific trade name |
| Storage conditions | Store at room temperature, protect from light and moisture |
| Chemical name | (1R,2R,3S,5S)-3-(3,4-Dichlorophenyl)-8-methyl-8-azabicyclo[3.2.1]octane-2-carboxylic acid phenylmethyl ester |
| Formula | C22H25Cl2NO3 |
| Substance class | Serotonin-noradrenaline-dopamine reuptake inhibitor |
| Main action | Inhibits the reuptake of serotonin, noradrenaline, and dopamine |
| Half-life | Approximately 11 hours |
| Dosage (medical) | Typically, 0.25 mg to 0.5 mg once daily |
| Dosage (sports) | Not recommended for sports usage |
| Effects | Appetite suppression, weight loss |
| Side effects | Dry mouth, nausea, constipation, hard stools, insomnia, and headache |
| Use in sports | Not advised due to potential for serious side effects and lack of approval for this use |
| Manufacturer | Beligas Pharmaceuticals |
| Packing | 100 tabs (0.25mg/tab) |
